The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2022

Filed:

Jan. 11, 2018
Applicant:

Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences, Guangdong, CN;

Inventors:

Jinyong Wang, Guangdong, CN;

Rongqun Guo, Guangdong, CN;

Mengyun Zhang, Guangdong, CN;

Lijuan Liu, Guangdong, CN;

Xiaofei Liu, Guangdong, CN;

Cui Lv, Guangdong, CN;

Juan Du, Guangdong, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 35/17 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12N 2500/00 (2013.01); C12N 2500/24 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/145 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/26 (2013.01); C12N 2501/999 (2013.01); C12N 2502/1394 (2013.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention provides a pluripotent stem cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stem cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stem cells. The pluripotent stem cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stem cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.


Find Patent Forward Citations

Loading…